Osteosarcoma

This trial is testing whether adding the targeted drug cabozantinib to standard chemotherapy (methotrexate, doxorubicin, and cisplatin) helps people with newly diagnosed osteosarcoma, a type of bone cancer. The study includes over 1,100 participants and aims to see if the combina…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. It includes 63 people aged 12 to 40. The goal is to see if the combination can stop the cancer from growing or delay its return.

This early-phase trial tests a new treatment called Attil12-T cell therapy for people with advanced soft tissue or bone sarcoma that has spread or cannot be removed. The therapy uses a patient's own immune cells, modified to target and attack the tumor. The main goals are to find…

This phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has come back or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. Researchers are checking whether the canc…

This phase 1 trial is testing a new treatment called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or does not respond to standard treatments. GD2CART is made by taking a patient's own T cells (a type of immune cell), adding a new gene…

This phase II trial tests a humanized antibody called Hu3F8 combined with GM-CSF (a drug that boosts the immune system) in children and young adults with recurrent osteosarcoma, a type of bone cancer. The goal is to see if this treatment can extend the time before the cancer retu…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests a new treatment using specially engineered immune cells (called CAR-NK cells) from donated cord blood, given alongside chemotherapy, for people with advanced kidney cancer, mesothelioma, or bone cancer. The goal is to find a safe dose and see if it helps control …

This early-phase trial tests the safety and effectiveness of the immune drug nivolumab (Opdivo) alone or combined with the chemo drug azacitidine (Vidaza) in people whose osteosarcoma has come back and can be surgically removed. About 21 participants will receive the drugs before…

This phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their t…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This phase II trial tests two immunotherapy drugs, oleclumab and durvalumab, in 75 people with advanced sarcoma (angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma) that has returned, spread, or stopped responding to treatment. The goal is to see if the combination can s…

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This study tests a daily oral drug called surufatinib in 47 people with advanced osteosarcoma or soft tissue sarcoma that has not responded to standard chemotherapy. The goal is to see if the drug can slow tumor growth and improve survival. Participants take the drug in 21-day cy…

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This phase 2 trial tests whether adding mifamurtide to standard chemotherapy helps people with high-risk osteosarcoma, a type of bone cancer. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive disease. Researchers will compare survival and relapse rates …

This study tests whether adding hydroxychloroquine (a malaria drug) to two chemotherapy drugs (gemcitabine and docetaxel) can help control osteosarcoma that has returned or stopped responding to treatment. About 31 participants will receive the combination to find the safest dose…

This study provided a single patient with recurrent osteosarcoma (a type of bone cancer) access to a personalized treatment made from their own tumor's genetic material. The therapy, called RNA-loaded lipid particles (RNA-LPs), was given intravenously to try to control the cancer…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…

This study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidne…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…

This study tests an experimental drug called HS-20093 against a standard chemotherapy combination (gemcitabine plus docetaxel) in people with osteosarcoma (a type of bone cancer) that has not responded to at least two prior treatments. About 117 participants aged 12 and older wil…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…

This early-phase trial tests whether specially engineered immune cells (HER2-specific CAR T cells) can safely treat advanced sarcoma that has not responded to standard treatments. Up to 36 participants will receive an infusion of their own modified T cells, with some also getting…

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells ca…

This early-phase trial tests a two-part treatment for osteosarcoma that has come back or not responded to standard care. First, a patient's own T cells are collected and genetically modified to become CAR T cells that can recognize a special flag. Then, after some chemotherapy, t…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This study tests whether combining two drugs, regorafenib and nivolumab, can help people with osteosarcoma (a type of bone cancer) that has returned or not responded to previous treatments. About 48 participants aged 5 and older will receive the combination. The main goal is to s…

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This study tests whether a single high dose of psilocybin (the active ingredient in magic mushrooms) combined with specialized talk therapy can help people with advanced cancer feel less anxious and more at peace. Fifteen adults with stage IV cancer will receive the treatment and…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This study looks at stored tissue samples from 100 people with advanced osteosarcoma to check for loss of the MTAP protein. Researchers want to see how common this loss is and whether it relates to cancer spread or immune system activity. No new treatment is given; the goal is to…

This study is testing whether a liquid biopsy (a blood test that detects tumor DNA) can help predict outcomes for people with Ewing sarcoma or osteosarcoma. Researchers will collect blood samples from 340 patients at diagnosis and track their health over time. The goal is to see …

This study analyzes tumor and blood samples from 763 people with bone cancer (osteosarcoma) to understand why some tumors resist chemotherapy. Researchers will test how cancer cells respond to drugs in the lab and look for genetic clues. The goal is to learn more about treatment …

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time p…

This study looks at why people with bone cancer (skeletal sarcoma) get more infections after joint replacement surgery than those with arthritis. Researchers will collect tissue and blood samples from 40 patients to compare immune and bacterial factors. The goal is to understand …

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…